iPSC-derived innate immune cell platform

CellOrigin Biotech (Hangzhou) Co., Ltd. is committed to the development of genetically engineered pluripotent stem cells (iPSC) derived immune cell therapies (such as macrophages, NK cells), with its own proprietary intellectual property. The founders are experienced leaders from Hengrui Pharma, AISO BIO, Harvard University and Zhejiang University. We apply metabolomics & transcriptomics analysis, functional CRISPR-Cas9 screen in iPSCs to deliver novel allogenic off-the-shelf cell therapies for the treatment of cancer patients around the world.